NetFlix Inc vs BIO-TECHNE Corp — how do they compare? NetFlix Inc trades at $71.71 (market cap $290.23B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: NetFlix Inc is far larger — about 25.5× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while NetFlix Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold NetFlix Inc for 125 Days and BIO-TECHNE Corp for 63 Days on average.
| NFLX | TECH | |
|---|---|---|
Market Cap | $290.23B | $11.37B |
Volume | 29,990,515 | 3,153,511 |
Sector | Media | Health |
52-Week High | $124.13 | $72.61 |
52-Week Low | $67.06 | $43.31 |
Typical Hold Time | 125 Days | 63 Days |
Enterprise Value | $295.41B | $11.40B |
Dividend Yield | — | 0.44% |
Signals from Pluang's Aura AI — not financial advice
Netflix (NFLX) trades at $71.58, up 4.21% with strong fundamental performance including 28.22% net income margin and consistent earnings beats. The stock shows bearish technical signals despite positive analyst sentiment with 64% buy ratings. Recent developments include expansion into live sports and content partnerships, while cash flow from operations reached $10.15 billion in 2025.
Netflix presents a compelling growth story with robust profitability and strategic expansion, though technical indicators suggest near-term caution. The 42% upside to consensus price target of $89.78 offers potential reward, but investors must weigh competitive pressures and content investment risks against the company's strong market position.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →